The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

A Subgroup Analysis of the FALCON Trial for HR+ Breast Cancer

John Robertson, MD
Published Online:4:50 PM, Wed March 1, 2017

John Robertson, MD, professor of Surgery, University of Nottingham, Royal Derby Hospital Centre, United Kingdom, discusses a subgroup analysis of the FALCON trial, which compared treatment with fulvestrant (Faslodex) versus anastrozole (Arimidex) in patients with HR-positive advanced breast cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.